TCMD
Tactile Systems Technology, Inc.
TCMD's fundamentals are strong: revenue grew 14% and earnings per share grew 32%, though free cash flow fell 27%. At 26x earnings, it's trading in line with its usual 27x. Analysts expect that strong growth to continue, though they disagree widely on how much.
TCMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Strong |
TCMD's profitability and balance sheet are currently healthy, and its revenue and cash flow are stable.
TCMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 13x | $13.15 | -51% |
| Forward | 21x | $26.82 | — |
| Current | 26x | $26.82 | — |
| Fair | 27x | $27.39 | +2.1% |
| Expensive | 89x | $91.05 | +240% |
Historical ranges are pointers, not guarantees.
TCMD's PE is in its fair range at 26x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
TCMD Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for TCMD, with profitability improving. However, they disagree widely on these estimates.
TCMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.25 | +23% |
| Q3 2026 | $1.02 | +32% |
| Q2 2026 | $1.07 | +73% |
| Q1 2026 | $0.87 | +32% |
| Q4 2025 | $0.82 | +17% |
| Q3 2025 | $0.77 | +13% |
| Q2 2025 | $0.62 | -56% |
| Q1 2025 | $0.66 | -46% |
| Q4 2024 | $0.70 | -43% |
TCMD's earnings per share have fallen from their peak: $1.02 over the past year, against $1.41 in mid-2024.
TCMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $91.9M | +7.1% |
| Q2 2026 | $85.7M | +8.6% |
| Q1 2026 | $75.3M | +23% |
| Q4 2025 | $103.6M | +21% |
| Q3 2025 | $85.8M | +17% |
| Q2 2025 | $78.9M | +7.8% |
| Q1 2025 | $61.3M | +0.3% |
| Q4 2024 | $85.6M | +10% |
TCMD's revenue has grown year over year for 22 quarters in a row: $92M last quarter, up 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | -2.3 points |
| Q2 2026 | 8% | +2.8 points |
| Q1 2026 | -2% | +5.4 points |
| Q4 2025 | 18% | +3.5 points |
| Q3 2025 | 13% | +3.5 points |
| Q2 2025 | 5.2% | -2.8 points |
| Q1 2025 | -7.4% | -2.6 points |
| Q4 2024 | 15% | -0.6 points |
TCMD's operating margin was 10% last quarter, down 2.3 points from the same quarter a year ago.
TCMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.4M | +24% |
| Q2 2026 | $2M | -86% |
| Q1 2026 | -$1.2M | -3153% |
| Q4 2025 | $16.8M | +5.8% |
| Q3 2025 | $9.2M | -0.9% |
| Q2 2025 | $14.4M | +14% |
| Q1 2025 | $38K | -91% |
| Q4 2024 | $15.9M | -9% |
TCMD generated $29M in free cash flow over the past year, down 27% from the year before.
TCMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -13K shares |
| 1 year | +2.4% | +533K shares |
| 3 years | -3.4% | -803K shares |
| 5 years | +16% | +3.3M shares |
| Available history | +17% | +3.4M shares |
TCMD has 23M diluted shares, up 2.4% from a year ago, despite $13M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6.2M |
| Q2 2026 | $5.3M |
| Q1 2026 | $1.1M |
| Q4 2025 | $1,000 |
| Q3 2025 | — |
| Q2 2025 | $16.5M |
| Q1 2025 | $10M |
TCMD spent $13M buying back its own shares over the past year.
TCMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.9x | Net Cash |
| Q2 2026 | -1.7x | Net Cash |
| Q1 2026 | -1.9x | Net Cash |
| Q4 2025 | -2.3x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.4x | Net Cash |
TCMD has more cash than debt.
TCMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.2 | Neutral |
| Stochastic | 45.3 | Neutral |
TCMD's weekly RSI is 57 (neutral) and its Stochastic is 45 (neutral).
TCMD PE vs Healthcare Sector
| Metric | TCMD | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 1.7% above |
| PE % | 49 | 29 | 20 pts above |
TCMD is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
TCMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.7 | 13% above |
| 20 week MA | $25.1 | 6.9% above |
| 50 week MA | $26.2 | 2.3% above |
| 100 week MA | $20.3 | 32% above |
| 200 week MA | $18.0 | 49% above |
TCMD is in an uptrend: it's above all five of its weekly moving averages, and 49% above its 200-week average.
TCMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $68.3 | $41.6 | -39% |
| 2021 | $41.6 | $20.2 | -51% |
| 2022 | $20.2 | $11.7 | -42% |
| 2023 | $11.7 | $14.3 | +22% |
| 2024 | $14.3 | $17.3 | +21% |
| 2025 | $17.3 | $29.7 | +72% |
| 2026 YTD | $29.7 | $26.8 | -9.6% |
TCMD has finished lower in three of the last six years. It's down 9.6% so far in 2026.